secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001193125-25-129524
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud

Intellia Therapeutics provides Phase 3 updates for NTLA-2002 and nex-z studies
------------------------------------------------------------------------------

- HAELO study enrollment on track; expect completion Q3 2025, BLA submission H2 2026, potential US launch 2027.
- MAGNITUDE-2 study of nex-z for ATTRv-PN progressing; BLA submission by 2028, potential US launch 2029.
- MAGNITUDE study for nex-z in ATTR-CM enrolled ~365 of 765 patients; enrollment completion expected early 2027.
- Over 200 patients dosed with nex-z in MAGNITUDE; adverse events similar to Phase 1; one asymptomatic grade 4 liver elevation resolving.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525129524/0001193125-25-129524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525129524/d40487d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-129524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer